What is the actual efficacy of cansezizumab?

Concizumab, a specific monoclonal antibody against tissue factor pathway inhibitor (TFPI), was developed by Novo Nordisk and won marketing approval from the U.S. Food and Drug Administration (FDA) in December 2024. Its trade name is Alhemo. This drug is designed for patients 12 years of age and older with hemophilia A or B, especially those with clotting factor inhibitors.

Cancelizumab binds to the Kunitz-2 domain of TFPI with high affinity, effectively inhibiting its activity, thereby blocking the interaction between TFPI and the active factor X, promoting the coagulation process and significantly reducing the occurrence of bleeding events. Data from multiple clinical trials have fully demonstrated the excellent efficacy of cancelizumab in the prevention and treatment of hemophilia. In Phase III clinical trial, patients with hemophilia A saw rates of spontaneous and traumatic bleeding reduced by up to 86%, and the corresponding bleeding rate in patients with hemophiliaB was also reduced by 79%. Another trial called explorer7 further showed that the average annual bleeding rate of the patient group receiving canezizumab was only 1.7 times, compared with the average annual bleeding rate of the patient group who did not receive preventive treatment (the average annual bleeding rate 11.8 times). The difference is extremely significant.

As a new biological agent, cancelizumab brings a new treatment option to patients with hemophilia. Its unique subcutaneous administration method allows patients to easily inject themselves at home using a pen-injector device, greatly improving the convenience of treatment and patient compliance.

However, the use of canezizumab is not without risks. In clinical trials, patients have reported thrombotic events. Although no new thromboembolic events were observed after adjustment, physicians still need to monitor patients closely for thromboembolic risk. In addition, injection site reactions, urticaria, and mild allergic reactions are also common side effects of cancelizumab.

To sum up, cancelizumab has shown excellent efficacy in preventing and treating hemophilia, providing patients with a new and effective treatment approach. However, when using this drug, doctors must fully evaluate the risks and benefits of the patient and pay close attention to changes in the patient's condition. Looking to the future, as more clinical trials are conducted in depth and long-term follow-up data continue to accumulate, we will have a more comprehensive and in-depth understanding of the efficacy and safety of cancelizumab.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761315s000lbl.pdf